Aclaris Therapeutics (ACRS) Cash from Investing Activities Growth (3y) (2017 - 2026)
Aclaris Therapeutics (ACRS) Cash from Investing Activities Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 46.78% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 66.14% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -39.73% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 296.32% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -53.57% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -246.81% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.84% |
| 10 | Aclaris Therapeutics | 808.18 Mn | 716.63 Mn | 1.41 Mn | 36.12% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36.12% |
| Mar 31, 2026 | -47.35% |
| Dec 31, 2025 | 56.56% |
| Sep 30, 2025 | 124.82% |
| Jun 30, 2025 | 30.80% |
| Mar 31, 2025 | -13.88% |
| Dec 31, 2024 | -113.04% |
| Sep 30, 2024 | 27.53% |
| Jun 30, 2024 | 75.44% |
| Mar 31, 2024 | 30.52% |
| Dec 31, 2023 | 74.08% |
| Sep 30, 2023 | 83.83% |
| Jun 30, 2023 | -23.31% |
| Mar 31, 2023 | 22.77% |
| Dec 31, 2022 | -63.69% |
| Sep 30, 2022 | -61.71% |
| Jun 30, 2022 | -46.12% |
| Mar 31, 2022 | 51.45% |
| Dec 31, 2021 | 49.32% |
| Sep 30, 2021 | -77.84% |